Search Results
Your search for ,Per matches 4038 pages
Showing 1001 - 1050Adhering to a Healthy Diet After a Head and Neck Cancer Diagnosis May Boost Survival
Patients with squamous cell carcinoma of the head or neck were 93% less likely to die of any cause during the first 3 years after diagnosis if they ate a healthy diet high in nutrients found to deter chronic disease, according to results published by Vieytes et al in Frontiers in Nutrition. The...
Long-Term Risk of Hospitalization for Infection in Childhood Cancer Survivors
In a population-based study reported in the Journal of Clinical Oncology, Chehab et al found that survivors of childhood cancer were at significantly increased risk of infections resulting in hospitalization vs comparators without cancer. Study Details The study involved children and adolescents...
Risk Stratification and Treatment Implications for Patients With Early-Stage Melanoma and Sentinel Node Metastasis
In a study reported in the Journal of Clinical Oncology, Moncrieff et al found that patients with stage IIIA melanoma (per American Joint Committee on Cancer [AJCC], 8th edition) with sentinel node metastatic tumor deposits ≥ 0.3 mm are at higher risk of disease progression vs those with smaller...
Meta-Analysis Examines Link Between Aspirin Use and Ovarian Cancer Risk
Frequent aspirin use may be linked with lower ovarian cancer risk in individuals with multiple risk factors, according to a new study published by Hurwitz et al in the Journal of Clinical Oncology. “Ovarian cancer is the most fatal gynecologic cancer. Most known risk factors of ovarian cancer—such...
Zandelisib in Continuous or Intermittent Dosing Schedules With or Without Rituximab for Relapsed or Refractory B-Cell Malignancies
In a first-in-patients phase Ib study reported in The Lancet Oncology, John M. Pagel, MD, PhD, and colleagues identified the safety profiles of the PI3Kδ inhibitor zandelisib given in intermittent vs continuous dosing schedules with or without rituximab in patients with relapsed of refractory...
Study Examines Role of Per- and Polyfluoroalkyl Substances in Development of Cancer, Health-Care Costs
Daily exposure to a class of chemicals used in the production of many household items may lead to cancer, thyroid disease, and childhood obesity, a new study published by Obsekov et al in the journal Exposure and Health showed. The resulting economic burden is estimated to cost Americans a minimum...
Diagnosing Basal Cell Carcinoma: Optical Coherence Tomography vs Punch Biopsy
In a Dutch trial reported in The Lancet Oncology, Adan et al found that optical coherence tomography (OCT)-guided diagnosis and treatment of basal cell carcinoma was noninferior to that with punch biopsy, currently the guideline-recommended standard for diagnosis and treatment. Study Details In the ...
ECHELON-1 Trial: Brentuximab Vedotin With Chemotherapy Offers Survival Benefit in Stage III or IV Hodgkin Lymphoma
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (a regimen known as A+AVD) significantly reduced the risk of mortality vs standard treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with previously untreated stage III or IV classical Hodgkin...
Medical Costs and Clinical Value: Playing the Long Game
Even as soaring medical costs strain public and private budgets around the world, patients yearn for therapeutic breakthroughs. Game-changing cancer treatments, emerging antiviral agents, and mRNA vaccines are powerful reminders of medical technology’s potential. But insurance premiums and...
Hematology Highlights From ASCO 2022
A multitude of presentations were available to attendees at the 2022 ASCO Annual Meeting, including hundreds in the hematologic malignancies tracks. In addition to coverage in The ASCO Post of the major news stories at the meeting, here we offer summaries of additional studies of special interest...
Noncytotoxic Maintenance With Niraparib Plus Either Nivolumab or Ipilimumab in Platinum-Sensitive Advanced Pancreatic Cancer
In a single-institution phase Ib/II trial reported in The Lancet Oncology, Kim A. Reiss, MD, and colleagues found that maintenance treatment with niraparib/ipilimumab produced better 6-month progression-free survival rates than niraparib/nivolumab in patients with advanced pancreatic cancer without ...
Expert Point of View: Susan Slovin, MD, PhD
Invited discussant Susan Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, pointed out there are no relevant serum biomarkers for disease progression and the challenges of interpreting response in metastatic castration-resistant prostate cancer. “We should have more definitive...
LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...
Rates of Major Adverse Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitors
In a single-institution Belgian study reported in the Journal of Clinical Oncology, Laenens et al found that major adverse cardiovascular events were “more common than currently appreciated” among patients receiving immune checkpoint inhibitors for cancer treatment. Study Details The study included ...
History of Radiation Oncology in the United States
Part 1 of this two-part report described the beginnings of radiation oncology in the United States, including many of the field’s early pioneers and the rise of associated professional societies. In part 2, we will consider the advances in technology and biology that are the foundation of modern...
Does Tumor Mutational Burden Influence Response to PD-1/PD-L1 Inhibitors Among Patients With Advanced NSCLC?
In a retrospective cohort study reported in JAMA Oncology, Ricciuti et al found that patients with advanced non–small cell lung cancer (NSCLC) with higher tumor mutational burden (TMB) had better outcomes with PD-1/PD-L1 inhibitor treatment vs those with lower TMB across thresholds of PD-L1...
Addition of Atezolizumab to Neoadjuvant Anti-HER2 Therapy and Chemotherapy in HER2-Positive Breast Cancer: IMpassion050
As reported in the Journal of Clinical Oncology by Jens Huober, MD, and colleagues, the phase III IMpassion050 trial showed no significant improvement in pathologic complete response rate with the addition of atezolizumab to neoadjuvant pertuzumab/trastuzumab and chemotherapy in patients with...
Physician Adenoma Detection Rates and Risk of Postcolonoscopy Colorectal Cancer: Is There a Correlation?
In a retrospective cohort study reported in JAMA, Schottinger et al found that patients treated by physicians with higher adenoma detection rates on colonoscopies negative for cancer had a lower risk of postcolonoscopy colorectal cancer and death from colorectal cancer. Study Details The study...
Screening Study to Identify Risk Factors for Breast Cancer–Related Lymphedema
In a prospective single-institution study reported in JAMA Oncology, Giacomo Montagna, MD, MPH, and colleagues found that the risk for breast cancer–related lymphedema after axillary lymph node dissection was increased in Black and Hispanic patients, those who received neoadjuvant chemotherapy, and ...
Outcomes in Pancreatic Cancer Surveillance Program for Carriers of Germline CDKN2A Pathogenic Variants
In a Dutch study reported in the Journal of Clinical Oncology, Klatte et al provided findings from a 20-year follow-up of a pancreatic cancer surveillance program including carriers of germline CDKN2A pathogenic variants. Study Details The study included 347 carriers in the Netherlands who...
Rucaparib Maintenance Improves Progression-Free Survival in Patients With Newly Diagnosed Advanced Ovarian Cancer Who Responded to Platinum-Based Therapy
Maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib led to a significant improvement in progression-free survival compared with placebo in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy. The...
NEJM Editors Publish Opinion Following Dobbs v Jackson Decision
On June 24, the editors of The New England Journal of Medicine (NEJM) published an editorial online in response to the U.S. Supreme Court (SCOTUS) decision in the case of Dobbs v Jackson Women’s Health Organization. The Court held in a vote of 5 to 4 that the Constitution of the United States does...
Risk of Interval Invasive and Advanced Breast Cancer: Screening With Digital Breast Tomosynthesis vs Digital Mammography
In a cohort study reported in JAMA, Karla Kerlikowske, MD, and colleagues found that screening with digital breast tomosynthesis (DBT) vs digital mammography was not associated with a lower risk of interval invasive breast cancer and was associated with a reduced risk of diagnosis of advanced...
History of Radiation Oncology in the United States
Radiation therapy has long been one of the three pillars of cancer therapy—surgery, chemotherapy, and radiotherapy—only recently joined by what is widely considered a fourth pillar, immunotherapy. In part 1 of this two-part report, we trace the beginnings of radiation oncology in the United...
Nivolumab/Cabozantinib vs Sunitinib in First-Line Treatment for Advanced RCC: Overall Survival Analysis of CheckMate 9ER Trial
As reported in The Lancet Oncology by Robert J. Motzer, MD, and colleagues, the protocol-defined final overall survival analysis of the phase III CheckMate 9ER trial showed a significant benefit with nivolumab/cabozantinib vs sunitinib in previously untreated patients with advanced renal cell...
Cancer Death Rates Among Black People Declined Over Time but Remain Higher Than Other Racial and Ethnic Groups
From 1999 to 2019, rates of cancer deaths declined steadily among Black people in the United States. Nevertheless, in 2019, Black people still had considerably higher rates of cancer death than people in other racial and ethnic groups, a large epidemiologic study has found. The study was led by...
American Cancer Society Investigators Present Studies on COVID-19 Pandemic, Racial/Ethnic Disparities, and Coverage for Genomic Testing
Investigators at the American Cancer Society presented results of several studies during poster sessions at the 2022 ASCO Annual Meeting. Summaries of a few of these studies are provided here. COVID-19 and Cancer Mortality According to a new study led by researchers at the American Cancer Society,...
NOTABLE Trial: Survival in Pancreatic KRAS Wild-Type Cancer Improved With Addition of Nimotuzumab to Gemcitabine
In patients with locally advanced or metastatic pancreatic cancer and KRAS wild-type tumors, novel treatment with the monoclonal antibody nimotuzumab, which targets the epidermal growth factor receptor (EGFR), plus gemcitabine significantly improved overall survival and other outcomes over...
Study Links Sugar-Sweetened Beverage Consumption and Liver Cancer Risk
A study of more than 90,000 postmenopausal women found that those who consumed at least one sugar-sweetened beverage daily faced a 78% higher risk of developing liver cancer compared with people who consumed less than three servings per month of such beverages. These findings were presented by Zhao ...
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer in Persons With HIV
In the phase III ANCHOR study reported in The New England Journal of Medicine, Palefsky et al found that treatment of high-grade squamous intraepithelial lesions was successful in preventing anal cancer vs active monitoring in persons infected with HIV. Study Details In the multicenter trial, 4,446 ...
Cabozantinib and Atezolizumab for Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Post–Hormonal Therapy
As reported in The Lancet Oncology by Neeraj Agarwal, MD, and colleagues, findings in the expansion cohort of the phase Ib COSMIC-021 trial indicate activity of the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer whose disease progressed ...
An Oncology Surgeon Leads Mexico’s Melanoma Program
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with surgical oncologist Héctor Martínez-Said, MD, of the Melanoma Clinic at NCI Mexico. Dr. Martínez-Said’s maternal grandfather was part of a Lebanese immigration movement...
Study Finds Diagnostic Mammography Performance Varies Across Racial and Ethnic Groups
The disparities in female breast cancer incidence and mortality among racial and ethnic groups is well documented. Studies show that while Black women have a lower incidence of breast cancer compared with White women, they are 41% more likely to die from the disease than White women. Breast cancer...
Overall Survival in Patients With Metastatic Colorectal Cancer in Phase III Trials and SEER Database Over a 30-Year Period
In a study reported in JAMA Network Open, Shen et al found that data from both phase III trials and the Surveillance, Epidemiology, and End Results (SEER) database indicate significant improvements in overall survival for patients with metastatic colorectal cancer over a 30-year period. Increases...
FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children as Young as 6 Months of Age
On June 17, the U.S. Food and Drug Administration (FDA) authorized emergency use of the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include use in children as young as 6 months of age. For the Moderna vaccine, the FDA amended the emergency...
Demethylation and Upregulation of the Oncogene SALL4 After Hypomethylating Therapy
In a study reported in The New England Journal of Medicine, Liu et al found that hypomethylating therapy was associated with upregulation of the oncogene SALL4 in a high proportion of patients with myelodysplastic syndrome. They also identified the gene region that is demethylated and responsible...
Potential Association of the 2012 USPSTF Grade D Recommendation Against PSA Screening With Changes in Prostate Cancer–Specific Mortality
In a study reported in JAMA Network Open, Burgess et al found that the 2012 U.S. Preventive Services Task Force (USPSTF) Grade D recommendation against prostate-specific antigen (PSA) screening for all men appeared to be associated with ending of a trend of annual reductions in prostate...
Metformin vs Placebo in Patients With High-Risk Operable Breast Cancer Receiving Standard Treatment
As reported in JAMA by Pamela J. Goodwin, MD, MSc, FRCPC, FASCO, the phase III MA.32 trial showed no invasive disease–free survival benefit with metformin vs placebo in patients without diabetes receiving standard therapy for high-risk nonmetastatic breast cancer. Study Details In the double-blind ...
T-DXd Shows Efficacy Against Active Brain Metastases in HER2-Positive Breast Cancer
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
Traditional Chinese Medicine Herbal Formula Ma Zi Ren Wan for Constipation
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Eugenie Spiguel, MSN, ANP-BS, and Jyothirmai Gubili, MS, focus on Ma Zi Ren...
Cemiplimab-rwlc Following Platinum-Based Chemotherapy in Recurrent or Metastatic Cervical Cancer: Clinical Implications
It is estimated that globally, more than 600,000 women per year are diagnosed with cervical cancer, and more than 300,000 die annually of the disease.1 Many women continue to be diagnosed with cervical cancer at an advanced stage, with a high risk of recurrence. To date, the most effective...
FLT3 Inhibitor Crenolanib in Combination With Chemotherapy for Newly Diagnosed Patients With FLT3-Mutant AML
Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, and colleagues presented the long-term results of a phase II clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for the treatment of adults with newly diagnosed ...
Did the ACA’S Medicaid Expansion Affect Cancer Clinical Trial Enrollment?
Researchers from the SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), found that the Affordable Care Act’s (ACA) expansion of Medicaid insurance in 2014 was followed by a significant increase in the proportion of patients enrolling in SWOG trials...
Panitumumab Plus mFOLFOX6 Improves Overall Survival in a Type of Newly Diagnosed Metastatic Colorectal Cancer
The use of panitumumab plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared with patients who received mFOLFOX6 plus bevacizumab, according to findings presented during the Plenary Session by...
New Report Shows COVID-19 Pandemic Increased Cancer-Related Deaths in the United States
According to a new study led by researchers at the American Cancer Society, the COVID-19 pandemic increased the number of cancer-related deaths by 3.2% in the United States from 2019 to 2020. Compared to 2019, the monthly cancer-related mortality rate was higher in April 2020, when health-care...
New Research Finds Computer-Assisted Colonoscopy May Identify More Precancerous Polyps Than Traditional Colonoscopy
Colonoscopies performed with computer-aided detection, or artificial intelligence (AI), saw an increase in the overall rate of detection of adenoma, or cancerous and precancerous polyps, by 27% in average-risk patients, according to new data presented by Shaukat et al at Digestive Disease Week 2022 ...
A Fascination With Bats Leads to a Career in Oncology and a Role in Championing Equity in the Workforce
According to internationally regarded neuroendocrine tumor specialist, Pamela Kunz, MD, her career path was kickstarted by childhood bat-hunting expeditions in barns and caves throughout rural New England. “My father was an environmental biologist at Boston University who studied bats. Although at...
After Rounds on the Leukemia Ward, a Young Doctor Finds His Calling in Stem Cell Transplantation
Internationally recognized stem cell transplant pioneer Richard E. Champlin, MD, was born in Milwaukee and moved to Homewood, a suburb on the southern lip of Chicago, with his parents when he was 3 years old. Following high school, Dr. Champlin entered Purdue University in Indiana to pursue a...
Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Stage IIIA NSCLC: Overall Survival and Biomarker Analyses
In analyses from a Spanish phase II trial (NADIM) reported in the Journal of Clinical Oncology, Provencio et al found a high rate of 3-year overall survival in patients with operable stage IIIA non–small cell lung cancer (NSCLC) who received neoadjuvant nivolumab plus chemotherapy. Survival was...
Association of Chronic Hepatitis B Virus Infection and Antiviral Treatment With Risk of Extrahepatic Malignancies
In a Korean nationwide cohort study reported in the Journal of Clinical Oncology, Lee et al found that patients with chronic hepatitis B infection were at increased risk of extrahepatic malignancies, with risk being reduced among those receiving nucleoside/nucleotide analog antiviral treatment for...
